Cetera Investment Advisers
PCRX icon

Cetera Investment Advisers’s Pacira BioSciences PCRX Stock Holding History

Cetera Investment Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
19,003
+2,733
+17% +$64.6K ﹤0.01% 3730
2026
Q1 		$368K Buy
16,270
+2,911
+22% +$64.7K ﹤0.01% 3804
2025
Q4 		$346K Buy
+13,359
New +$318K ﹤0.01% 3770

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's PCRX Position: Q2 2026 in Review

Cetera Investment Advisers increased its Pacira BioSciences (PCRX) stake by 17% in Q2 2026, buying an estimated $64.6K and bringing the position to 19,003 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #3730.

Cetera Investment Advisers first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Cetera Investment Advisers held 19,003 shares of Pacira BioSciences worth $482K as of Q2 2026.
  • Cetera Investment Advisers bought 2,733 Pacira BioSciences shares in Q2 2026, an estimated $64.6K.
  • Pacira BioSciences made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3730 holding.
  • Cetera Investment Advisers first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.